Patent medicine name
Imbruvica 140mg 90 Capsule
Manufacturer
Janssen Pharmaceuticals
Specification
Physical Form: Capsule, Quantity: 90/bottle, Storage: Room Temperature(10-30°C)
Price
$4200-4500
Generic medicine name & Manufacturer
Ibrucent 140mg 90 Capsule, Incepta
Specification
Physical Form: Capsule, Quantity: 90/bottle, Storage: Room Temperature(10-30°C)
Price
$675-680
Composition
Ibrutinib 140mg
Use
Mantle cell lymphoma (MCL) who have received at least one prior treatment
Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL
Medicince introduction including background, function, caution, etc.
Indication
Ibrutinib is indicated for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Waldenstrom’s Macroglobulinemia, Marginal zone Lymphoma, Chronic Graft Versus Host Disease. Ibrutinib is a first line treatment in those with CLL who require treatment and are newly diagnosed. It may also be used in CLL that relapses.
Sideeffects
Bleeding, Leukostasis, Infections, Decrease the blood cell counts, Heart problems, Liver problems.
Mechanisam of Action
Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It forms a covalent bond with a cysteine residue in the active site of BTK (Cys481), leading to its inhibition. The inhibition of BTK plays a role in the B-cell receptor signaling and thus, the presence of ibrutinib prevents the phosphorylation of downstream substrates such as PLC-γ
Use in Other language
Picture